Platform study designed to rapidly screen potential Covid-19 drugs enrolls first patients – MedCity News

Three of the companies making drugs used in the Phase II I-SPY COVID-19 study – Amgen, AbbVie and Takeda – announced the patient enrollments Monday. The study, which will enroll up to 1,500 critically ill patients, could test around 10 drugs.

Read the full article here

Related Articles